A Phase II Study of Docetaxel and Vinorelbine in Advanced Non-Small Cell Lung Carcinoma

Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically or cytologically confirmed stage IIIB or IV
non-small cell lung cancer Bidimensionally measurable or evaluable disease No symptomatic
brain metastases

PATIENT CHARACTERISTICS: Age: Over 18 Performance status: Karnofsky 70-100% Life
expectancy: Greater than 2 months Hematopoietic: Absolute neutrophil count at least
2,000/mm3 Platelet count at least 100,000/mm3 Hepatic: AST and ALT no greater than 1.5
times upper limit of normal (ULN) Bilirubin no greater than ULN Renal: Creatinine no
greater than 2.0 mg/dL Cardiovascular: No uncontrolled hypertension, unstable angina,
congestive heart failure, or atrial or ventricular arrhythmias At least 6 months since
prior myocardial infarction Other: Not pregnant or nursing Negative pregnancy test Fertile
patients must use effective contraception HIV negative No poorly controlled diabetes No
known allergy to E. coli derivatives or any products to be administered No other prior
malignancy within the past 5 years except surgically cured basal cell skin cancer or
carcinoma in situ of the cervix No active infection or fever Not previously entered in
this study

PRIOR CONCURRENT THERAPY: Biologic therapy: No other concurrent hematopoietic growth
factors Chemotherapy: No prior chemotherapy Endocrine therapy: Not specified Radiotherapy:
At least 2 weeks since prior radiotherapy and recovered Surgery: At least 2 weeks since
prior major thoracic or abdominal surgery and recovered At least 6 months since prior
coronary angioplasty Other: At least 30 days since prior investigational agents No other
concurrent investigational agent No prophylactic acetaminophen for fever